No Photo Available

Last Update

2016-11-27T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Alan Rigby?

Dr. Alan C. Rigby

Assistant Professor, Division of Hemostasis and Thrombosis, Department of Medicine

Beth Israel Deaconess Medical Center

HQ Phone: (617) 667-7000

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Beth Israel Deaconess Medical Center

SL-401 330 Brookline Ave.

Boston, Massachusetts 02215

United States

Company Description

Beth Israel Deaconess Medical Center (BIDMC) is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is in the c ... more

Find other employees at this company (5,536)

Background Information

Employment History

Assistant Professor of Medicine, Director, Program

Harvard Medical School

Assistant Professor of Medicine

Harvard University

Assistant Professor of Medicine

Harvard Medical International

Affiliations

Scientific Advisory Board Member
Cambridge Healthtech Institute

Founder, SAB Member
Karyon Therapeutics

Education

Ph.D. Assistant

Professor of Medicine Harvard Medical School Center for Vascular Biology Research Division of Molecular and Vascular Medicine Division of Interdisciplinary Medicine and Biotechnology Department of Medicine Beth Israel Deaconess Medical Center

PhD

University of Western Ontario

Web References (19 Total References)


Faculty | Beth Israel Deaconess Medical Center

www.bidmc.org [cached]

Alan C. Rigby, PhD

...
Alan C. Rigby, PhD Research area:


Faculty

www.healthtech.com [cached]

Alan Rigby, Ph.D.,Assistant Professor of Medicine,Harvard Medical School; Director, Program in Drug Discovery and Target Validation, Beth Israel Deaconess Medical Center


TieCon East

tieconeast.org [cached]

Alan Rigby

...
Alan Rigby Assistant Professor of Medicine Harvard Medical School
...
Dr. Alan Rigby is structural biologist working at the interface of structural and computational biology in developing and validating the utility of partnering NMR spectroscopy with in silico screening. His research program is focused on the use of this powerful approach for the exploration and druggable validation of targeting novel chemical space that is the cornerstone of: protein-protein, protein-ligand and protein-DNA interactions in the areas of blood coagulation, apoptosis, gene regulation, inflammation and cancer. Dr Rigby received his PhD from the University of Western Ontario, London, Ontario, Canada with distinction and completed his postdoctoral fellowship at Tufts University School of Medicine and Harvard Medical School when his mentor was recruited to Harvard. Dr Rigby is currently an Assistant Professor of Medicine at Harvard Medical School. Dr Rigby is in the Division of Molecular and Vascular Medicine and a member of the Center for Vascular Biology Research at the Beth Israel Deaconess Medical Center.


Research Groups and Projects

www.mdibl.org [cached]

*Alan C. Rigby, Ph.D., Assistant Professor of Medicine, Beth Israel Deaconess Medical Center


Towia Libermann, PhD, Alan ...

semiconductors.ulitzer.com [cached]

Towia Libermann, PhD, Alan Rigby, PhD - Beth Israel Deaconess Medical Center

Development and Validation of Selective Small Molecule Ets Factor Inhibitors for Prostate Cancer -Understanding Gene Activity that Likely Causes Up to 60 Percent of Prostate Cancer Can Open Door to New Drug Development-Another Approach
The genetic alteration present in 40-60% of prostate cancer cases gives rise to expression of Ets factors that drive the initiation and progression of prostate cancer. Identification of the Ets factor binding sites on DNA is the first step in selecting candidate inhibitors of the highly carcinogenic event. Unlike Proposal #1 by Dr. Barbara Graves, where advanced molecular biology biotechnologies will be used to identify these sites, Drs. Libermann and Rigby will use state-of-the-art computer-aided drug design methods to model the structure of these sites.

Similar Profiles

Other People with this Name

Other people with the name Rigby

Meghan Rigby
McGehee School

Carl Rigby
Monadelphous

Eimear Rigby
Camomille Associates Limited

Raynard Rigby
Baycourt Chambers

Amanda Rigby
m3property

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory